Sydney West Translational Cancer Research Centre
Forgot Password?

Defining the value of comparative oncology clinical trials in companion species

Comparative Oncology SIG



New Law School Seminar Room 028 Eastern Avenue The University of Sydney (Camperdown campus)

The CRN Comparative Oncology Special Interest Group invites you to a lecture by:

Professor David M Vail, DVM Diplomate ACVIM (Oncology)
Professor and Barbara A. Suran Chair in Comparative Oncology, University of Wisconsin-Madison

RSVP : Registration is not required. All welcome.

Comparative oncology integrates the study of naturally occurring cancers in animals into studies of human cancer biology and therapy. The term is most often used when referring to the study of cancers seen in companion (pet) animals. Over the past decade, tremendous growth in the field has occurred, including significant increases in organised consortium infrastructure, availability of investigational reagents and regulatory standardisation. These advances are currently being applied to the development of novel cytotoxic, immunologic, and biology-based anticancer therapies, innovative drug delivery systems, identification and validation of biological endpoints, noninvasive imaging techniques and surrogate markers critical to the design of Phase I and Phase II human clinical trials. Additionally, the biotechnology and pharmaceutical industries recognise the utility of comparative oncology and several examples exist where studies have been initiated in companion species to assist in human cancer drug development. Consideration of the questions that can be asked within the comparative oncology approach define the translational value of this approach. Several examples will be presented that illustrate the types of questions that have been successfully answered within comparative oncology studies.

The CRN Comparative Oncology Special Interest Group (CO-SIG) aims to develop a multidisciplinary biomedical, diagnostic pipeline by linking clinicians, oncologists, epidemiologists and molecular researchers, pursuing broad-based clinical and interdisciplinary approaches for an increased understanding and treatment of cancer.

The CO-SIG also aims to promote and enhance discussion between human and animal cancer researchers for the mutual benefit of both communities.